Fig. 2From: Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trialSchedule of enrollment, interventions, and assessments (SPIRIT checklist)Back to article page